Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

AIDS

Volumn 26, Issue 14, 2012, Pages 1765-1774

  Peluso, Michael J ^a   Ferretti, Francesca ^b   Peterson, Julia ^c   Lee, Evelyn ^c   Fuchs, Dietmar ^d   Boschini, Antonio ^e   Gisslén, Magnus ^f   Angoff, Nancy ^a   Price, Richard W ^c   Cinque, Paola ^b   Spudich, Serena ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e San Patrignano Medical Centre   (Italy)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

antiretroviral therapy; central nervous system; cerebrospinal fluid; HIV; HIV drug resistance; HIV pathogenesis; neurologic manifestations

Indexed keywords

ANTIRETROVIRUS AGENT; BRAIN PROTEIN; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; PRIORITY JOURNAL; SENSORY DYSFUNCTION; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; EUROPE; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; RETROSPECTIVE STUDIES; RNA, VIRAL; UNITED STATES; URBAN POPULATION; VIRAL LOAD;

EID: 84866340305     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328355e6b2     Document Type: Article

References (32)

1. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrosp-inal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21:271-276. (Pubitemid 29357657)
2. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
3. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42:679-688. (Pubitemid 27481539)
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neuro-cognitive disorders. Neurology 2007; 69:1789-1799. (Pubitemid 350059308)
5. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197 (Suppl 3):S294-S306. (Pubitemid 351717319)
6. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, et al. Changing incidence of central nervous system diseases in the Euro SIDA cohort. Ann Neurol 2004; 55:320-328. (Pubitemid 38292033)
7. Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-1825.
8. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
9. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
10. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
11. Del Palacio Tamarit M, Quereda C, Gonzalez-Rozas M, Corral I, Casado JL. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28:83-86.
12. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 2011; 63:236-239.
13. van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis 2010; 50:387-390.
14. Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS 2011; 22:608-609.
15. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
16. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
17. Letendre S, Ellis R, Deutsch R, Clifford D, Marra C, McCutchan A, Morgello S, et al. The CHARTER Group. Correlates of time-to-loss-of-viral- response in CSF and plasma in the CHARTER cohort. In: program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
18. Corcoran C, Rebe K, van der Plas H, Myer L, Hardie DR. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42:433-436.
19. Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen A, et al. Determination of neopterin in serum and urine. Clin Chem 1987; 33:62-66. (Pubitemid 17104095)
20. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich SS, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomar-ker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7:15.
21. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002; 16:1019-1022.
22. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005; 79:10830-10834. (Pubitemid 41098622)
23. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000; 14:1949-1954.
24. Lanier ER, Sturge G, McClernon D, et al. HIV-1 reverse tran-scriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with abacavir. AIDS 2001; 15:747-751. (Pubitemid 32423222)
25. Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol 1995; 33:352-355.
26. Stingele K, Haas J, Zimmermann T, Stingele R, Hubsch-Muller C, Freitag M, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001; 56:355-361. (Pubitemid 32144147)
27. Bestetti A, Presi S, Pierotti C, Bossolasco S, Sala S, Racca S, et al. Long-term virological effect of highly active anti-retroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol 2004; 10 (Suppl 1): 52-57. (Pubitemid 38325094)
28. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, et al. Effects of central nervous system antiretro-viral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25:357-365.
29. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686-1689.
30. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3:175-187. (Pubitemid 34326529)
31. Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol 2005; 42:183-194. (Pubitemid 39361448)
32. Miller RF, Isaacson PG, Hall-Craggs M, Lucas S, Gray F, Scaravilli F, et al. Cerebral CD8R lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004; 108:17-23. (Pubitemid 38961068)